DrugPatentWatch Database Preview
Details for Patent: 8,138,195
Which drugs does patent 8,138,195 protect, and when does it expire?
This patent has fifty-three patent family members in twenty-nine countries.
Summary for Patent: 8,138,195
Title: | Inhibitors of human phosphatidylinositol 3-kinase delta |
Abstract: | Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K.delta. plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K.delta., while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3K.delta. activity, including compounds that selectively inhibit PI3K.delta. activity. Methods of using PI3K.delta. inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3K.delta. inhibitory compounds to inhibit PI3K.delta.-mediated processes in vitro and in vivo. |
Inventor(s): | Sadhu; Chanchal (Bothell, WA), Dick; Kenneth O. (Bothell, WA), Treiberg; Jennifer (Bothell, WA), Sowell; C. Gregory (Mukilteo, WA), Kesicki; Edward A. (Bothell, WA), Oliver; Amy (Bothell, WA) |
Assignee: | ICOS Corporation (Bothell, WA) |
Application Number: | 11/110,204 |
Patent Claim Types: see list of patent claims | Compound; Use; Composition; |
Drugs Protected by US Patent 8,138,195
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences Inc | ZYDELIG | idelalisib | TABLET;ORAL | 205858-001 | Jul 23, 2014 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA | ➤ Try a Free Trial | ||
Gilead Sciences Inc | ZYDELIG | idelalisib | TABLET;ORAL | 205858-002 | Jul 23, 2014 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA | ➤ Try a Free Trial | ||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 8,138,195
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
9,487,772 | Inhibitors of human phosphatidylinositol 3-kinase delta | ➤ Try a Free Trial |
8,637,533 | Inhibitors of human phosphatidylinositol 3-kinase delta | ➤ Try a Free Trial |
6,800,620 | Inhibitors of human phosphatidylinositol 3-kinase delta | ➤ Try a Free Trial |
6,949,535 | Inhibitors of human phosphatidyl-inositol 3-kinase delta | ➤ Try a Free Trial |
Patent No. | Title | Estimated Patent Expiration |
International Family Members for US Patent 8,138,195
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Denmark | 1278748 | ➤ Try a Free Trial | |||
China | 1440408 | ➤ Try a Free Trial | |||
China | 1606444 | ➤ Try a Free Trial | |||
Cyprus | 1116299 | ➤ Try a Free Trial | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |